Targeted therapy for bone cancer
Targeted therapy uses drugs that seek out and attach themselves to proteins, receptors or gene mutations found only on specific types of cancer cells. Targeted therapy drugs may be used alone to kill cancer cells, or in combination with chemotherapy or other treatments, help anti-cancer drugs better identify and attack cancer cells.
Common targeted therapy drugs used to treat bone cancer include:
Imatinib (Gleevec®): This targeted drug, used to treat some patients with specific gene mutations, may be recommended to treat chordomas— tumors that generally grow along the spine or the base of the skull—that have metastasized or returned after previous treatment.
Denosumab (Prolia®, Xgeva®): This monoclonal antibody may be used to treat metastatic bone cancer and help prevent bone loss.
Zoledronic acid (Reclast®, Zometa®, Aclasta®): This drug is a bisphosphonate, which may be used to reduce the risk of bone complications, such as fractures.